Steven Goodman

Steven Goodman is a seasoned professional in process development and manufacturing within the biotechnology sector, currently serving as Vice President of Process Development for Cell and Genetic Therapies at Vertex Pharmaceuticals since December 2020. Goodman's expertise spans gene-modified cell therapies and adeno-associated virus (AAV) processes, building on prior leadership roles at bluebird bio and GSK where responsibilities included overseeing global contract manufacturing organizations and managing supply chain strategies for cell and gene therapy products. Academic credentials include a Postdoctoral Fellowship and Ph.D. in Organic Chemistry from Harvard University and a joint BS/MS degree in Chemistry from Yale University.